Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease.

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Visca, D.
- Centis, R.
- Pontali, E.
- Zampogna, E.
- Russell, A. -M.
- Migliori, G. B.
- Andrejak, C.
- Aro, M.
- Bayram, H.
- Berkani, K.
- Bruchfeld, J.
- Chakaya, J. M.
- Chorostowska-Wynimko, J.
- Crestani, B.
- Dalcolmo, M. P.
- D'Ambrosio, L.
- Dinh-Xuan, A-T.
- Duong-Quy, S.
- Fernandes, C.
- Garcia-Garcia, J. -M.
- de Melo Kawassaki, A
- Carrozzi, L.
- Martins, P. Carreiro
- Mirsaeidi, M.
- Mohammad, Y.
- Naidoo, R. N.
- Neuparth, N.
- Sese, L.
- Silva, D. R.
- Solovic, I.
- Sooronbaev, T. M.
- Spanevello, A.
- Sverzellati, N.
- Tanno, L.
- Tiberi, S.
- Vasankari, T.
- Vasarmidi, E.
- Vitacca, M.
- Annesi-Maesano, I.
Grupos
Abstract
BACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice' care for the diagnosis, treatment and prevention of post-COVID-19 lung disease.METHODS: A panel of international experts representing scientific societies, associations and groups active in post-COVID-19 lung disease was identified; 45 completed a Delphi process. A 5-point Likert scale indicated level of agreement with the draft standards. The final version was approved by consensus (with 100% agreement).RESULTS: Four clinical standards were agreed for patients with a previous history of COVID-19: Standard 1, Patients with sequelae not explained by an alternative diagnosis should be evaluated for possible post-COVID-19 lung disease; Standard 2, Patients with lung function impairment, reduced exercise tolerance, reduced quality of life (QoL) or other relevant signs or ongoing symptoms =4 weeks after the onset of first symptoms should be evaluated for treatment and pulmonary rehabilitation (PR); Standard 3, The PR programme should be based on feasibility, effectiveness and cost-effectiveness criteria, organised according to local health services and tailored to an individual patient's needs; and Standard 4, Each patient undergoing and completing PR should be evaluated to determine its effectiveness and have access to a counselling/health education session.CONCLUSION: This is the first consensus-based set of clinical standards for the diagnosis, treatment and prevention of post-COVID-19 lung disease. Our aim is to improve patient care and QoL by guiding clinicians, programme managers and public health officers in planning and implementing a PR programme to manage post-COVID-19 lung disease.
Datos de la publicación
- ISSN/ISSNe:
- 1027-3719, 1815-7920
- Tipo:
- Article
- Páginas:
- 729-741
- PubMed:
- 37749839
- Factor de Impacto:
- 0,845 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- long COVID; SARS-COV-2; post-COVID conditions; pulmonary rehabilitation; quality of life
Proyectos y Estudios Clínicos
INTENSIFICACION DR. MIGUEL MARTINEZ GARCIA
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
INT11/037 . 2012
ASOCIACION ENTRE TRASTORNOS RESPIRATORIOS DEL SUEÑO Y TASA DE CRECIMIENTO DEL MELANOMA CUTANEO
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PI12/01363 . INSTITUTO DE SALUD CARLOS III . 2013
EFECTO DEL TRATAMIENTO CON CPAP SOBRE LAS CIFRAS TENSIONALES EN PACIENTES CON HIPERTENSION ARTERIAL REFRACTARIA. ESTUDIO MULTICENTRICO Y ALEATORIZADO. ESTUDIO HIPARCO
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PI09/01647 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010
INTENSIFICACION DR. MIGUEL ANGEL MARTINEZ GARCIA
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
INT14/00003 . INSTITUTO DE SALUD CARLOS III . 2015
ASOCIACIÓN ENTRE LOS TRASTORNOS RESPIRATORIOS DEL SUEÑO Y EL PRONÓSTICO DEL MELANOMA. ESTUDIO LONGITUDINAL Y MULTICÉNTRICO EN 443 PACIENTES CON MELANOMA CUTÁNEO MALIGNO.
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PI16/01772 . INSTITUTO DE SALUD CARLOS III . 2017
P4COPD: Prediction, Prevention, Personalized and Precision management of COPD in young adults.
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PMP21/00090 . INSTITUTO DE SALUD CARLOS III . 2022
Registro nacional de antibóticos inhalados en patología crónica de la vía área.
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
REPAIR . 2023